Literature DB >> 32222950

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease.

Laura A Bosmans1, Lena Bosch2, Pascal J H Kusters1,3, Esther Lutgens1,4,5, Tom T P Seijkens6.   

Abstract

Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment of classical cardiovascular risk factors, a substantial portion of the population has elevated inflammatory biomarkers and develops atherosclerosis-related complications, indicating that a residual inflammatory risk drives atherosclerotic cardiovascular disease in these patients. Additional anti-inflammatory therapeutic strategies are therefore required. The co-stimulatory molecule CD40 and its ligand CD40L (CD154) have a central role in the regulation of the inflammatory response during the development of atherosclerosis by modulating the interaction between immune cells and between immune cells and non-immune cells. In this review, we discuss the role of the CD40-CD40L dyad in atherosclerosis, and we discuss recent studies on the therapeutic potential of novel CD40-CD40L targeting strategies in cardiovascular medicine.

Entities:  

Keywords:  Atherosclerosis; CD40; CD40L; Cardiovascular disease; Immune checkpoint proteins; Inflammation

Year:  2020        PMID： 32222950      PMCID： PMC7892683          DOI： 10.1007/s12265-020-09994-3

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN： 1937-5387            Impact factor:   4.132


  76 in total

1.  Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma.

Authors:  J Thom; G Gilmore; Q Yi; G J Hankey; J W Eikelboom
Journal:  J Thromb Haemost       Date:  2004-11       Impact factor: 5.824

2.  Blocking α5β1 Integrin Attenuates sCD40L-Mediated Platelet Activation.

Authors:  Damir Simic; Nancy Bogdan; Fang Teng; Monicah Otieno
Journal:  Clin Appl Thromb Hemost       Date:  2015-12-29       Impact factor: 2.389

3.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.

Authors:  Jean-Claude Tardif; Simon Kouz; David D Waters; Olivier F Bertrand; Rafael Diaz; Aldo P Maggioni; Fausto J Pinto; Reda Ibrahim; Habib Gamra; Ghassan S Kiwan; Colin Berry; José López-Sendón; Petr Ostadal; Wolfgang Koenig; Denis Angoulvant; Jean C Grégoire; Marc-André Lavoie; Marie-Pierre Dubé; David Rhainds; Mylène Provencher; Lucie Blondeau; Andreas Orfanos; Philippe L L'Allier; Marie-Claude Guertin; François Roubille
Journal:  N Engl J Med       Date:  2019-11-16       Impact factor: 91.245

4.  CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism.

Authors:  Patrick André; K S Srinivasa Prasad; Cécile V Denis; Ming He; Jessie M Papalia; Richard O Hynes; David R Phillips; Denisa D Wagner
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

5.  Complement regulation in human atherosclerotic coronary lesions. Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway.

Authors:  Riina Oksjoki; Petri T Kovanen; Mikko I Mäyränpää; Petri Laine; Anna M Blom; Seppo Meri; Markku O Pentikäinen
Journal:  Atherosclerosis       Date:  2006-07-18       Impact factor: 5.162

6.  Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling.

Authors:  K S Srinivasa Prasad; Patrick Andre; Ming He; Ming Bao; Jeanne Manganello; David R Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

Review 7.  CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications.

Authors:  Tom Seijkens; Pascal Kusters; David Engel; Esther Lutgens
Journal:  Diab Vasc Dis Res       Date:  2012-09-10       Impact factor: 3.291

8.  Systemic blood coagulation activation in acute coronary syndromes.

Authors:  Anetta Undas; Konstanty Szułdrzyński; Kathleen E Brummel-Ziedins; Wiesława Tracz; Krzysztof Zmudka; Kenneth G Mann
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

9.  The SNP rs1883832 in CD40 gene and risk of atherosclerosis in Chinese population: a meta-analysis.

Authors:  Yan Yun; Chi Ma; XiaoChun Ma
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

10.  Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort.

Authors:  Alexander Peikert; Klaus Kaier; Julian Merz; Lucas Manhart; Ibrahim Schäfer; Ingo Hilgendorf; Philipp Hehn; Dennis Wolf; Florian Willecke; Xia Sheng; Andreas Clemens; Manfred Zehender; Constantin von Zur Mühlen; Christoph Bode; Andreas Zirlik; Peter Stachon
Journal:  Clin Res Cardiol       Date:  2019-07-19       Impact factor: 5.460
View more
  9 in total

Review 1.  Novel Functions of Integrins as Receptors of CD154: Their Role in Inflammation and Apoptosis.

Authors:  Ghada S Hassan; Suzanne Salti; Walid Mourad
Journal:  Cells       Date:  2022-05-25       Impact factor: 7.666

2.  In vivo CD40 Silencing by siRNA Infusion in Rodents and Evaluation by Kidney Immunostaining.

Authors:  Miguel Hueso; Adrián Mallén; Elia Ripoll; Laura de Ramón; Núria Bolaños; Cristian Varela; Jordi Guiteras; Javier Checa; Estanislao Navarro; Josep Maria Grinyo; Josep Maria Cruzado; Josep Maria Aran; Joan Torras
Journal:  Bio Protoc       Date:  2021-05-20

3.  Paeoniflorin and Hydroxysafflor Yellow A in Xuebijing Injection Attenuate Sepsis-Induced Cardiac Dysfunction and Inhibit Proinflammatory Cytokine Production.

Authors:  Xin-Tong Wang; Zhen Peng; Ying-Ying An; Ting Shang; Guangxu Xiao; Shuang He; Xi Chen; Han Zhang; Yuefei Wang; Tao Wang; Jun-Hua Zhang; Xiumei Gao; Yan Zhu; Yuxin Feng
Journal:  Front Pharmacol       Date:  2021-04-13       Impact factor: 5.810

Review 4.  Roles of Macrophages in Atherogenesis.

Authors:  Lia Farahi; Satyesh K Sinha; Aldons J Lusis
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

Review 5.  Role of CD40(L)-TRAF signaling in inflammation and resolution-a double-edged sword.

Authors:  Lea Strohm; Henning Ubbens; Thomas Münzel; Andreas Daiber; Steffen Daub
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

6.  Elevation of CD40/CD40L Inflammatory Pathway Molecules in Carotid Plaques from Moderate-and-Severe Obstructive Sleep Apnea Patients.

Authors:  Ewa Migacz; Wioletta Olejarz; Alicja Głuszko; Katarzyna Bednarek-Rajewska; Robert Proczka; David F Smith; Stacey L Ishman; Wojciech Kukwa
Journal:  Diagnostics (Basel)       Date:  2021-05-22

Review 7.  B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications.

Authors:  Tanyaporn Pattarabanjird; Cynthia Li; Coleen McNamara
Journal:  JACC Basic Transl Sci       Date:  2021-06-28

Review 8.  CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease-The Pros and Cons for Cardioprotection.

Authors:  Steffen Daub; Esther Lutgens; Thomas Münzel; Andreas Daiber
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

9.  Immuno-PET Imaging of Atherosclerotic Plaques with [89Zr]Zr-Anti-CD40 mAb-Proof of Concept.

Authors:  Kikkie Poels; Maxime Schreurs; Matthijs Jansen; Danielle J Vugts; Tom T P Seijkens; Guus A M S van Dongen; Esther Lutgens; Wissam Beaino
Journal:  Biology (Basel)       Date:  2022-03-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.